Nufarm（NUF）株式概要Nufarm Limited は、その子会社とともに、ヨーロッパ、中東、アフリカ、北米、アジア太平洋地域で作物保護ソリューションと種子技術の開発、製造、販売を行っている。 詳細NUF ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長3/6過去の実績0/6財務の健全性5/6配当金0/6報酬収益は年間91.08%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析リスクチェックの結果、NUF 、リスクは検出されなかった。すべてのリスクチェックを見るNUF Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€1.4488.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-557m4b2016201920222025202620282031Revenue AU$4.3bEarnings AU$418.8mAdvancedSet Fair ValueView all narrativesFeatured narrative•Materials opportunityUpside Gold2 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 割安 内在価値ディスカウントAn Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative15.1kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative286users have followed this narrativeRead narrativeNufarm Limited 競合他社K+SSymbol: XTRA:SDFMarket cap: €2.8bSIMONASymbol: DB:SIM0Market cap: €342.0mUzin UtzSymbol: XTRA:UZUMarket cap: €350.1mSto SE KGaASymbol: XTRA:STO3Market cap: €641.3m価格と性能株価の高値、安値、推移の概要Nufarm過去の株価現在の株価AU$1.4452週高値AU$2.2852週安値AU$1.02ベータ0.191ヶ月の変化11.63%3ヶ月変化19.01%1年変化-33.33%3年間の変化-56.36%5年間の変化-54.72%IPOからの変化-72.57%最新ニュースお知らせ • Mar 28+ 1 more updateNufarm Limited to Report First Half, 2026 Results on May 27, 2026Nufarm Limited announced that they will report first half, 2026 results on May 27, 2026お知らせ • Nov 20Nufarm Limited, Annual General Meeting, Feb 04, 2026Nufarm Limited, Annual General Meeting, Feb 04, 2026. Location: hybrid meeting, Australiaお知らせ • May 27Nufarm Reportedly Receives Takeover Interest for NuseedAs of May 23, 2025 Nufarm Limited (ASX:NUF)'s share price was down about 38% over five days with its market value at $1 billion, close to the price at which the company's Seed Technologies unit Nuseed Pty. Ltd. is valued. The Seed Technologies unit is now subject to a UBS-run strategic review, which could lead to a sale, after groups such as BP and the KKR-backed Advanta Enterprises Limited expressed interest. A suitor may determine it is better to buy the entire company that was worth double what it is currently trading at a year ago, potentially attracting private -equity suitors. However, one deterrent could be its debt pile, with net debt at $1.36 billion. If a buyer for its $900 million Seed Technologies business cannot be sought, analysts are not ruling out an equity raising.お知らせ • Apr 29+ 1 more updateNufarm Limited to Report First Half, 2025 Results on May 21, 2025Nufarm Limited announced that they will report first half, 2025 results on May 21, 2025お知らせ • Mar 24Nufarm Limited(ASX:NUF) dropped from FTSE All-World Index (USD)Nufarm Limited(ASX:NUF) dropped from FTSE All-World Index (USD)お知らせ • Dec 12Nufarm Limited Announces Nutriterra® Total Omega-3 Receives Health Canada Approval as Plant-Based Dietary SupplementNutriterra®? Total Omega-3 has received Health Canada approval as an ingredient in dietary supplements. Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) issued a product license, Natural Product Number (NPN) 80136254, which authorizes it to be marketed and sold as a novel, canola-based total omega-3 oil with the following health claims: Supports heart health and cardiovascular function; Supports normal brain function; Source of docosahexaenoic acid (DHA) for maintaining good health; Source of alpha-linolenic acid (ALA) for maintaining good health; source of an essential fatty acid for the maintenance of good health; Source of omega-3 fatty acids for the maintenance of good health. Human clinical trials confirmed that Nutriterra's long-chain fatty acids are readily incorporated into blood lipids. Results were reviewed and authorized by NNHPD and published in Frontiers in Nutrition in 2022. A 2000 mg/day serving of Nutriterra significantly improved indicators of omega-3 status, including the OmegaScore™? and the Omega-3 Index, both of which are supportive of cardiovascular and brain health. While the health benefits of omega-3 fatty acids are well known, few people consume enough of these essential nutrients. Ms. Boettner attributes this to the sensory experiences and ocean health concerns associated with fish oil. This approval follows the Canadian Food Inspection Agency's 2020 approval of Nutriterra for food and feed applications, allowing for greater formulation flexibility for customers. Omega-3 Canola helps fill the gap between how much long-chain omega-3 is needed to support human health and how little the ocean can sustainably provide. Just one hectare of Nuseed Omega-3 canola produces as much DHA as 10,000 one kg wild caught fish. Nutriterra has a unique fatty acid profile with DHA, EPA, and ALA to support human nutrition. This Health Canada approval follows the US Food and Drug Administration (FDA) granting Nutriterra New Dietary Ingredient status in 2021. Having previously obtained food and feed approvals in Australia and New Zealand, the US, and Canada, the company is progressing with additional regulatory applications in other key markets around the world.最新情報をもっと見るRecent updatesお知らせ • Mar 28+ 1 more updateNufarm Limited to Report First Half, 2026 Results on May 27, 2026Nufarm Limited announced that they will report first half, 2026 results on May 27, 2026お知らせ • Nov 20Nufarm Limited, Annual General Meeting, Feb 04, 2026Nufarm Limited, Annual General Meeting, Feb 04, 2026. Location: hybrid meeting, Australiaお知らせ • May 27Nufarm Reportedly Receives Takeover Interest for NuseedAs of May 23, 2025 Nufarm Limited (ASX:NUF)'s share price was down about 38% over five days with its market value at $1 billion, close to the price at which the company's Seed Technologies unit Nuseed Pty. Ltd. is valued. The Seed Technologies unit is now subject to a UBS-run strategic review, which could lead to a sale, after groups such as BP and the KKR-backed Advanta Enterprises Limited expressed interest. A suitor may determine it is better to buy the entire company that was worth double what it is currently trading at a year ago, potentially attracting private -equity suitors. However, one deterrent could be its debt pile, with net debt at $1.36 billion. If a buyer for its $900 million Seed Technologies business cannot be sought, analysts are not ruling out an equity raising.お知らせ • Apr 29+ 1 more updateNufarm Limited to Report First Half, 2025 Results on May 21, 2025Nufarm Limited announced that they will report first half, 2025 results on May 21, 2025お知らせ • Mar 24Nufarm Limited(ASX:NUF) dropped from FTSE All-World Index (USD)Nufarm Limited(ASX:NUF) dropped from FTSE All-World Index (USD)お知らせ • Dec 12Nufarm Limited Announces Nutriterra® Total Omega-3 Receives Health Canada Approval as Plant-Based Dietary SupplementNutriterra®? Total Omega-3 has received Health Canada approval as an ingredient in dietary supplements. Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) issued a product license, Natural Product Number (NPN) 80136254, which authorizes it to be marketed and sold as a novel, canola-based total omega-3 oil with the following health claims: Supports heart health and cardiovascular function; Supports normal brain function; Source of docosahexaenoic acid (DHA) for maintaining good health; Source of alpha-linolenic acid (ALA) for maintaining good health; source of an essential fatty acid for the maintenance of good health; Source of omega-3 fatty acids for the maintenance of good health. Human clinical trials confirmed that Nutriterra's long-chain fatty acids are readily incorporated into blood lipids. Results were reviewed and authorized by NNHPD and published in Frontiers in Nutrition in 2022. A 2000 mg/day serving of Nutriterra significantly improved indicators of omega-3 status, including the OmegaScore™? and the Omega-3 Index, both of which are supportive of cardiovascular and brain health. While the health benefits of omega-3 fatty acids are well known, few people consume enough of these essential nutrients. Ms. Boettner attributes this to the sensory experiences and ocean health concerns associated with fish oil. This approval follows the Canadian Food Inspection Agency's 2020 approval of Nutriterra for food and feed applications, allowing for greater formulation flexibility for customers. Omega-3 Canola helps fill the gap between how much long-chain omega-3 is needed to support human health and how little the ocean can sustainably provide. Just one hectare of Nuseed Omega-3 canola produces as much DHA as 10,000 one kg wild caught fish. Nutriterra has a unique fatty acid profile with DHA, EPA, and ALA to support human nutrition. This Health Canada approval follows the US Food and Drug Administration (FDA) granting Nutriterra New Dietary Ingredient status in 2021. Having previously obtained food and feed approvals in Australia and New Zealand, the US, and Canada, the company is progressing with additional regulatory applications in other key markets around the world.Reported Earnings • Nov 15Full year 2024 earnings released: AU$0.068 loss per share (vs AU$0.26 profit in FY 2023)Full year 2024 results: AU$0.068 loss per share (down from AU$0.26 profit in FY 2023). Revenue: AU$3.35b (down 3.9% from FY 2023). Net loss: AU$5.60m (down 106% from profit in FY 2023). Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Aug 18Independent Non-Executive Chairman recently bought €176k worth of stockOn the 16th of August, John Gillam bought around 75k shares on-market at roughly €2.35 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.Declared Dividend • May 26First half dividend of AU$0.04 announcedShareholders will receive a dividend of AU$0.04. Ex-date: 29th May 2024 Payment date: 14th June 2024 Dividend yield will be 2.5%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments.Reported Earnings • May 24First half 2024 earnings released: EPS: AU$0.10 (vs AU$0.38 in 1H 2023)First half 2024 results: EPS: AU$0.10 (down from AU$0.38 in 1H 2023). Revenue: AU$1.76b (down 10% from 1H 2023). Net income: AU$39.5m (down 73% from 1H 2023). Profit margin: 2.2% (down from 7.4% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.お知らせ • Mar 06+ 2 more updatesNufarm Limited to Report First Half, 2024 Results on May 16, 2024Nufarm Limited announced that they will report first half, 2024 results on May 16, 2024お知らせ • Nov 22Nufarm Limited, Annual General Meeting, Feb 01, 2024Nufarm Limited, Annual General Meeting, Feb 01, 2024.お知らせ • Nov 17Nufarm Limited Announces Final Dividend for the Period of Six Months Ended 30 September 2023, Payable on 15 December 2023Nufarm Limited announced final dividend of AUD 0.05000000 per share for the period of six months ended 30 September 2023. Ex Date 22 November 2023, Record Date 23 November 2023 and Payment Date 15 December 2023.お知らせ • Nov 15Nufarm Limited Announces Director ResignationsNufarm Limited announced the resignation of Gordon Davis and Peter Margin as non-executive directors of the Nufarm board, effective November 15, 2023. This completes a 3-year period of board renewal. Gordon Davis joined the Nufarm board on 31 May 2011 following a distinguished executive career in the agribusiness and industrial sectors including as managing director of AWB and senior executive roles at Orica and Incitec Fertilizers. During his 12 year tenure at Nufarm, Gordon served on numerous board committees, including most recently as chair of the risk and compliance committee and previously as chair of the health, safety and environment committee. Peter Margin joined the Nufarm board on 3 October 2011, bringing a wealth of experience in consumer marketing, manufacturing and operations from his executive roles as managing director at National Foods and Goodman Fielder, in addition to his various non executive roles including at Bega Group, Costa and Asahi Beverages. Peter also served on numerous committees during his tenure, most notably chairing the human resources committee for more than 10 years.Buying Opportunity • Jul 25Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 2.4%. The fair value is estimated to be €4.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.0% per annum. Earnings is also forecast to grow by 9.9% per annum over the same time period.Board Change • Jul 02High number of new directorsIndependent Non-Executive Director Federico Tripodi was the last director to join the board, commencing their role in 2023.お知らせ • Jun 19Nufarm Limited Announces Board ChangesNufarm Limited announced the appointment of Adrian Percy and Federico Tripodi as independent, non-executive directors of the Nufarm Board. These appointments are the final step in a three-year board renewal process, which will conclude later this year with the previously announced retirements of long serving directors Peter Margin and Gordon Davis. Adrian is currently the inaugural Executive Director of the NC Plant Sciences Initiative at North Carolina State University. He has more than 30 years of experience in the agricultural sector, with previous roles as Chief Technology Officer of UPL Ltd. and Head of Research and Development for the Crop Science Division of Bayer. In the latter role, he was a member of their Executive Committee with responsibility for internal and open innovation activities in the areas of crop protection chemistry and biologicals, as well as seeds and traits. During his 25-year tenure at Bayer, he also held numerous positions in agricultural research and development. Adrian is a Venture Partner at Finistere Ventures LLC, a technology and life sciences venture capital investor. He also serves on the board of directors of BioLumic, AgPlenus, FA Bio and Evogene. Adrian holds a BSc from University of Liverpool, an MSc in Toxicology from University of Birmingham and a PhD in Biochemistry from University of Birmingham. He will take up his appointment to the Nufarm board with effect from 1 July 2023 and will stand for election at Nufarm’s Annual General Meeting (AGM) in February 2024. Federico has close to three-decades of involvement in the agri-food sector with his experience spanning general management, research and development, corporate strategy and the commercialization of novel plant biotechnologies targeted for consumers and farmers. Federico currently serves as Chairman at the Agricultural Utilization Research Institute (AURI). He is also the Founder and CEO of Blacktop Holdings, a boutique venture lab that offers strategic and operating partnership services to rapidly growing Ag Tech, Food and Agribusiness companies, their investors and research institutions. From 2016 to 2018, Federico served as the CEO of Calyxt Inc. Prior to Calyxt, Federico worked at Monsanto Company for nearly two decades where his primary focus was developing health, sustainability and renewable energy crop products in the United States and Latin America. Federico holds an MBA from Washington University’s Olin Business School, as well as an agronomic engineering degree from Buenos Aires University. He will take up his appointment to the Nufarm board with effect from today’s date and will stand for election at Nufarm’s AGM in February 2024.Buying Opportunity • May 19Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be €4.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings is also forecast to grow by 13% per annum over the same time period.お知らせ • May 18Nufarm Limited Announces Distribution for the Six Months Ended March 31, 2023, Payable on June 9, 2023Nufarm Limited announced distribution of AUD 0.05000000 per share for the six months ended March 31, 2023. Record date is May 26, 2023. Ex-date is May 25, 2023. Payment date is June 9, 2023.Reported Earnings • May 18First half 2023 earnings released: EPS: AU$0.38 (vs AU$0.25 in 1H 2022)First half 2023 results: EPS: AU$0.38 (up from AU$0.25 in 1H 2022). Revenue: AU$1.95b (down 9.7% from 1H 2022). Net income: AU$149.0m (up 57% from 1H 2022). Profit margin: 7.6% (up from 4.4% in 1H 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Mar 26MD, CEO & Executive Director recently bought €50k worth of stockOn the 20th of March, Gregory Hunt bought around 15k shares on-market at roughly €3.33 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gregory has been a buyer over the last 12 months, purchasing a net total of €141k worth in shares.お知らせ • Nov 18Nufarm Limited, Annual General Meeting, Feb 02, 2023Nufarm Limited, Annual General Meeting, Feb 02, 2023.Reported Earnings • Nov 17Full year 2022 earnings released: EPS: AU$0.26 (vs AU$0.15 in FY 2021)Full year 2022 results: EPS: AU$0.26 (up from AU$0.15 in FY 2021). Revenue: AU$3.77b (up 17% from FY 2021). Net income: AU$99.9m (up 73% from FY 2021). Profit margin: 2.6% (up from 1.8% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years, in line with the revenue forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Recent Insider Transactions • May 25MD, CEO & Executive Director recently bought €91k worth of stockOn the 24th of May, Gregory Hunt bought around 25k shares on-market at roughly €3.65 per share. This was the largest purchase by an insider in the last 3 months. This was Gregory's only on-market trade for the last 12 months.Reported Earnings • May 20First half 2022 earnings releasedFirst half 2022 results: Revenue: (flat on 1H 2021). Net income: (flat on 1H 2021). Profit margin: (in line with 1H 2021). Over the next year, revenue is expected to shrink by 6.1% compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Buying Opportunity • Apr 23Now 23% undervaluedOver the last 90 days, the stock is up 56%. The fair value is estimated to be €5.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.1% per annum. Earnings is also forecast to grow by 20% per annum over the same time period.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 29% share price gain to €3.48, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 11x in the Chemicals industry in Germany. Total loss to shareholders of 2.8% over the past three years.Reported Earnings • Nov 17Full year 2021 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$3.22b (up 100% from FY 2020). Net income: AU$65.1m (up AU$613.2m from FY 2020). Profit margin: 2.0% (up from net loss in FY 2020). The move to profitability was driven by higher revenue.Breakeven Date Change • Jul 31Forecast breakeven pushed back to 2022The 12 analysts covering Nufarm previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of AU$75.3m in 2022. Average annual earnings growth of 33% is required to achieve expected profit on schedule.Recent Insider Transactions • May 26MD, CEO & Executive Director recently bought €61k worth of stockOn the 24th of May, Gregory Hunt bought around 20k shares on-market at roughly €3.07 per share. This was the largest purchase by an insider in the last 3 months. Gregory has been a buyer over the last 12 months, purchasing a net total of €180k worth in shares.Is New 90 Day High Low • Feb 26New 90-day high: €3.20The company is up 28% from its price of €2.50 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.12 per share.Is New 90 Day High Low • Feb 04New 90-day high: €3.08The company is up 45% from its price of €2.12 on 06 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.69 per share.Is New 90 Day High Low • Jan 20New 90-day high: €2.84The company is up 27% from its price of €2.24 on 22 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.53 per share.Is New 90 Day High Low • Oct 21New 90-day low: €2.24The company is down 10.0% from its price of €2.48 on 22 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.89 per share.Is New 90 Day High Low • Oct 02New 90-day low: €2.28The company is down 8.0% from its price of €2.48 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.00 per share.Recent Insider Transactions • Sep 30Chairman of the Board recently bought €452k worth of stockOn the 28th of September, John Gillam bought around 185k shares on-market at roughly €2.44 per share. This was the largest purchase by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.株主還元NUFDE ChemicalsDE 市場7D0.7%-3.9%-0.02%1Y-33.3%2.2%0.1%株主還元を見る業界別リターン: NUF過去 1 年間で2.2 % の収益を上げたGerman Chemicals業界を下回りました。リターン対市場: NUFは、過去 1 年間で0.1 % のリターンを上げたGerman市場を下回りました。価格変動Is NUF's price volatile compared to industry and market?NUF volatilityNUF Average Weekly Movement8.0%Chemicals Industry Average Movement5.6%Market Average Movement6.0%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.6%安定した株価: NUF 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: NUFの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19163,068Rico Christensenwww.nufarm.comNufarm Limited は子会社とともに、ヨーロッパ、中東、アフリカ、北米、アジア太平洋地域で作物保護ソリューションと種子技術の開発、製造、販売を行っている。同社は、作物保護と種子技術の分野で事業を展開している。同社は、除草剤、殺虫剤、殺菌剤を提供し、生産者が雑草、害虫、病気から作物を守るのを支援している。また、ベースとなる種子、バイオエネルギー、オメガ3、種子処理プラットフォームを運営し、種子や油性製品の販売も行っている。また、穀物、トウモロコシ、大豆、牧草、芝、観葉植物、樹木、木の実、つる植物、野菜などの作物にも注力している。さらに、同社は昆虫、菌類、病気による被害の保護と治療のための種子処理製品を提供している。さらに、ヒマワリ、ソルガム、カノーラの種子を販売している。同社は1916年に設立され、オーストラリアのラバートン・ノースに本社を置いている。もっと見るNufarm Limited 基礎のまとめNufarm の収益と売上を時価総額と比較するとどうか。NUF 基礎統計学時価総額€581.25m収益（TTM）-€115.00m売上高(TTM)€2.12b0.3xP/Sレシオ-5.1xPER（株価収益率NUF は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NUF 損益計算書（TTM）収益AU$3.44b売上原価AU$2.49b売上総利益AU$950.13mその他の費用AU$1.14b収益-AU$186.98m直近の収益報告Sep 30, 2025次回決算日May 27, 2026一株当たり利益（EPS）-0.49グロス・マージン27.59%純利益率-5.43%有利子負債／自己資本比率54.3%NUF の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 08:45終値2026/05/07 00:00収益2025/09/30年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nufarm Limited 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21 アナリスト機関Stephen WilderAlliance Global PartnersJonathan SnapeBell PotterMiriam PritchardBofA Global Research18 その他のアナリストを表示
Featured narrative•Materials opportunityUpside Gold2 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 割安 内在価値ディスカウントAn Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative15.1kusers have viewed this narrative42users have liked this narrative1users have commented on this narrative286users have followed this narrativeRead narrative
お知らせ • Mar 28+ 1 more updateNufarm Limited to Report First Half, 2026 Results on May 27, 2026Nufarm Limited announced that they will report first half, 2026 results on May 27, 2026
お知らせ • Nov 20Nufarm Limited, Annual General Meeting, Feb 04, 2026Nufarm Limited, Annual General Meeting, Feb 04, 2026. Location: hybrid meeting, Australia
お知らせ • May 27Nufarm Reportedly Receives Takeover Interest for NuseedAs of May 23, 2025 Nufarm Limited (ASX:NUF)'s share price was down about 38% over five days with its market value at $1 billion, close to the price at which the company's Seed Technologies unit Nuseed Pty. Ltd. is valued. The Seed Technologies unit is now subject to a UBS-run strategic review, which could lead to a sale, after groups such as BP and the KKR-backed Advanta Enterprises Limited expressed interest. A suitor may determine it is better to buy the entire company that was worth double what it is currently trading at a year ago, potentially attracting private -equity suitors. However, one deterrent could be its debt pile, with net debt at $1.36 billion. If a buyer for its $900 million Seed Technologies business cannot be sought, analysts are not ruling out an equity raising.
お知らせ • Apr 29+ 1 more updateNufarm Limited to Report First Half, 2025 Results on May 21, 2025Nufarm Limited announced that they will report first half, 2025 results on May 21, 2025
お知らせ • Mar 24Nufarm Limited(ASX:NUF) dropped from FTSE All-World Index (USD)Nufarm Limited(ASX:NUF) dropped from FTSE All-World Index (USD)
お知らせ • Dec 12Nufarm Limited Announces Nutriterra® Total Omega-3 Receives Health Canada Approval as Plant-Based Dietary SupplementNutriterra®? Total Omega-3 has received Health Canada approval as an ingredient in dietary supplements. Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) issued a product license, Natural Product Number (NPN) 80136254, which authorizes it to be marketed and sold as a novel, canola-based total omega-3 oil with the following health claims: Supports heart health and cardiovascular function; Supports normal brain function; Source of docosahexaenoic acid (DHA) for maintaining good health; Source of alpha-linolenic acid (ALA) for maintaining good health; source of an essential fatty acid for the maintenance of good health; Source of omega-3 fatty acids for the maintenance of good health. Human clinical trials confirmed that Nutriterra's long-chain fatty acids are readily incorporated into blood lipids. Results were reviewed and authorized by NNHPD and published in Frontiers in Nutrition in 2022. A 2000 mg/day serving of Nutriterra significantly improved indicators of omega-3 status, including the OmegaScore™? and the Omega-3 Index, both of which are supportive of cardiovascular and brain health. While the health benefits of omega-3 fatty acids are well known, few people consume enough of these essential nutrients. Ms. Boettner attributes this to the sensory experiences and ocean health concerns associated with fish oil. This approval follows the Canadian Food Inspection Agency's 2020 approval of Nutriterra for food and feed applications, allowing for greater formulation flexibility for customers. Omega-3 Canola helps fill the gap between how much long-chain omega-3 is needed to support human health and how little the ocean can sustainably provide. Just one hectare of Nuseed Omega-3 canola produces as much DHA as 10,000 one kg wild caught fish. Nutriterra has a unique fatty acid profile with DHA, EPA, and ALA to support human nutrition. This Health Canada approval follows the US Food and Drug Administration (FDA) granting Nutriterra New Dietary Ingredient status in 2021. Having previously obtained food and feed approvals in Australia and New Zealand, the US, and Canada, the company is progressing with additional regulatory applications in other key markets around the world.
お知らせ • Mar 28+ 1 more updateNufarm Limited to Report First Half, 2026 Results on May 27, 2026Nufarm Limited announced that they will report first half, 2026 results on May 27, 2026
お知らせ • Nov 20Nufarm Limited, Annual General Meeting, Feb 04, 2026Nufarm Limited, Annual General Meeting, Feb 04, 2026. Location: hybrid meeting, Australia
お知らせ • May 27Nufarm Reportedly Receives Takeover Interest for NuseedAs of May 23, 2025 Nufarm Limited (ASX:NUF)'s share price was down about 38% over five days with its market value at $1 billion, close to the price at which the company's Seed Technologies unit Nuseed Pty. Ltd. is valued. The Seed Technologies unit is now subject to a UBS-run strategic review, which could lead to a sale, after groups such as BP and the KKR-backed Advanta Enterprises Limited expressed interest. A suitor may determine it is better to buy the entire company that was worth double what it is currently trading at a year ago, potentially attracting private -equity suitors. However, one deterrent could be its debt pile, with net debt at $1.36 billion. If a buyer for its $900 million Seed Technologies business cannot be sought, analysts are not ruling out an equity raising.
お知らせ • Apr 29+ 1 more updateNufarm Limited to Report First Half, 2025 Results on May 21, 2025Nufarm Limited announced that they will report first half, 2025 results on May 21, 2025
お知らせ • Mar 24Nufarm Limited(ASX:NUF) dropped from FTSE All-World Index (USD)Nufarm Limited(ASX:NUF) dropped from FTSE All-World Index (USD)
お知らせ • Dec 12Nufarm Limited Announces Nutriterra® Total Omega-3 Receives Health Canada Approval as Plant-Based Dietary SupplementNutriterra®? Total Omega-3 has received Health Canada approval as an ingredient in dietary supplements. Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) issued a product license, Natural Product Number (NPN) 80136254, which authorizes it to be marketed and sold as a novel, canola-based total omega-3 oil with the following health claims: Supports heart health and cardiovascular function; Supports normal brain function; Source of docosahexaenoic acid (DHA) for maintaining good health; Source of alpha-linolenic acid (ALA) for maintaining good health; source of an essential fatty acid for the maintenance of good health; Source of omega-3 fatty acids for the maintenance of good health. Human clinical trials confirmed that Nutriterra's long-chain fatty acids are readily incorporated into blood lipids. Results were reviewed and authorized by NNHPD and published in Frontiers in Nutrition in 2022. A 2000 mg/day serving of Nutriterra significantly improved indicators of omega-3 status, including the OmegaScore™? and the Omega-3 Index, both of which are supportive of cardiovascular and brain health. While the health benefits of omega-3 fatty acids are well known, few people consume enough of these essential nutrients. Ms. Boettner attributes this to the sensory experiences and ocean health concerns associated with fish oil. This approval follows the Canadian Food Inspection Agency's 2020 approval of Nutriterra for food and feed applications, allowing for greater formulation flexibility for customers. Omega-3 Canola helps fill the gap between how much long-chain omega-3 is needed to support human health and how little the ocean can sustainably provide. Just one hectare of Nuseed Omega-3 canola produces as much DHA as 10,000 one kg wild caught fish. Nutriterra has a unique fatty acid profile with DHA, EPA, and ALA to support human nutrition. This Health Canada approval follows the US Food and Drug Administration (FDA) granting Nutriterra New Dietary Ingredient status in 2021. Having previously obtained food and feed approvals in Australia and New Zealand, the US, and Canada, the company is progressing with additional regulatory applications in other key markets around the world.
Reported Earnings • Nov 15Full year 2024 earnings released: AU$0.068 loss per share (vs AU$0.26 profit in FY 2023)Full year 2024 results: AU$0.068 loss per share (down from AU$0.26 profit in FY 2023). Revenue: AU$3.35b (down 3.9% from FY 2023). Net loss: AU$5.60m (down 106% from profit in FY 2023). Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Aug 18Independent Non-Executive Chairman recently bought €176k worth of stockOn the 16th of August, John Gillam bought around 75k shares on-market at roughly €2.35 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.
Declared Dividend • May 26First half dividend of AU$0.04 announcedShareholders will receive a dividend of AU$0.04. Ex-date: 29th May 2024 Payment date: 14th June 2024 Dividend yield will be 2.5%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments.
Reported Earnings • May 24First half 2024 earnings released: EPS: AU$0.10 (vs AU$0.38 in 1H 2023)First half 2024 results: EPS: AU$0.10 (down from AU$0.38 in 1H 2023). Revenue: AU$1.76b (down 10% from 1H 2023). Net income: AU$39.5m (down 73% from 1H 2023). Profit margin: 2.2% (down from 7.4% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.
お知らせ • Mar 06+ 2 more updatesNufarm Limited to Report First Half, 2024 Results on May 16, 2024Nufarm Limited announced that they will report first half, 2024 results on May 16, 2024
お知らせ • Nov 22Nufarm Limited, Annual General Meeting, Feb 01, 2024Nufarm Limited, Annual General Meeting, Feb 01, 2024.
お知らせ • Nov 17Nufarm Limited Announces Final Dividend for the Period of Six Months Ended 30 September 2023, Payable on 15 December 2023Nufarm Limited announced final dividend of AUD 0.05000000 per share for the period of six months ended 30 September 2023. Ex Date 22 November 2023, Record Date 23 November 2023 and Payment Date 15 December 2023.
お知らせ • Nov 15Nufarm Limited Announces Director ResignationsNufarm Limited announced the resignation of Gordon Davis and Peter Margin as non-executive directors of the Nufarm board, effective November 15, 2023. This completes a 3-year period of board renewal. Gordon Davis joined the Nufarm board on 31 May 2011 following a distinguished executive career in the agribusiness and industrial sectors including as managing director of AWB and senior executive roles at Orica and Incitec Fertilizers. During his 12 year tenure at Nufarm, Gordon served on numerous board committees, including most recently as chair of the risk and compliance committee and previously as chair of the health, safety and environment committee. Peter Margin joined the Nufarm board on 3 October 2011, bringing a wealth of experience in consumer marketing, manufacturing and operations from his executive roles as managing director at National Foods and Goodman Fielder, in addition to his various non executive roles including at Bega Group, Costa and Asahi Beverages. Peter also served on numerous committees during his tenure, most notably chairing the human resources committee for more than 10 years.
Buying Opportunity • Jul 25Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 2.4%. The fair value is estimated to be €4.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.0% per annum. Earnings is also forecast to grow by 9.9% per annum over the same time period.
Board Change • Jul 02High number of new directorsIndependent Non-Executive Director Federico Tripodi was the last director to join the board, commencing their role in 2023.
お知らせ • Jun 19Nufarm Limited Announces Board ChangesNufarm Limited announced the appointment of Adrian Percy and Federico Tripodi as independent, non-executive directors of the Nufarm Board. These appointments are the final step in a three-year board renewal process, which will conclude later this year with the previously announced retirements of long serving directors Peter Margin and Gordon Davis. Adrian is currently the inaugural Executive Director of the NC Plant Sciences Initiative at North Carolina State University. He has more than 30 years of experience in the agricultural sector, with previous roles as Chief Technology Officer of UPL Ltd. and Head of Research and Development for the Crop Science Division of Bayer. In the latter role, he was a member of their Executive Committee with responsibility for internal and open innovation activities in the areas of crop protection chemistry and biologicals, as well as seeds and traits. During his 25-year tenure at Bayer, he also held numerous positions in agricultural research and development. Adrian is a Venture Partner at Finistere Ventures LLC, a technology and life sciences venture capital investor. He also serves on the board of directors of BioLumic, AgPlenus, FA Bio and Evogene. Adrian holds a BSc from University of Liverpool, an MSc in Toxicology from University of Birmingham and a PhD in Biochemistry from University of Birmingham. He will take up his appointment to the Nufarm board with effect from 1 July 2023 and will stand for election at Nufarm’s Annual General Meeting (AGM) in February 2024. Federico has close to three-decades of involvement in the agri-food sector with his experience spanning general management, research and development, corporate strategy and the commercialization of novel plant biotechnologies targeted for consumers and farmers. Federico currently serves as Chairman at the Agricultural Utilization Research Institute (AURI). He is also the Founder and CEO of Blacktop Holdings, a boutique venture lab that offers strategic and operating partnership services to rapidly growing Ag Tech, Food and Agribusiness companies, their investors and research institutions. From 2016 to 2018, Federico served as the CEO of Calyxt Inc. Prior to Calyxt, Federico worked at Monsanto Company for nearly two decades where his primary focus was developing health, sustainability and renewable energy crop products in the United States and Latin America. Federico holds an MBA from Washington University’s Olin Business School, as well as an agronomic engineering degree from Buenos Aires University. He will take up his appointment to the Nufarm board with effect from today’s date and will stand for election at Nufarm’s AGM in February 2024.
Buying Opportunity • May 19Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be €4.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings is also forecast to grow by 13% per annum over the same time period.
お知らせ • May 18Nufarm Limited Announces Distribution for the Six Months Ended March 31, 2023, Payable on June 9, 2023Nufarm Limited announced distribution of AUD 0.05000000 per share for the six months ended March 31, 2023. Record date is May 26, 2023. Ex-date is May 25, 2023. Payment date is June 9, 2023.
Reported Earnings • May 18First half 2023 earnings released: EPS: AU$0.38 (vs AU$0.25 in 1H 2022)First half 2023 results: EPS: AU$0.38 (up from AU$0.25 in 1H 2022). Revenue: AU$1.95b (down 9.7% from 1H 2022). Net income: AU$149.0m (up 57% from 1H 2022). Profit margin: 7.6% (up from 4.4% in 1H 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Mar 26MD, CEO & Executive Director recently bought €50k worth of stockOn the 20th of March, Gregory Hunt bought around 15k shares on-market at roughly €3.33 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gregory has been a buyer over the last 12 months, purchasing a net total of €141k worth in shares.
お知らせ • Nov 18Nufarm Limited, Annual General Meeting, Feb 02, 2023Nufarm Limited, Annual General Meeting, Feb 02, 2023.
Reported Earnings • Nov 17Full year 2022 earnings released: EPS: AU$0.26 (vs AU$0.15 in FY 2021)Full year 2022 results: EPS: AU$0.26 (up from AU$0.15 in FY 2021). Revenue: AU$3.77b (up 17% from FY 2021). Net income: AU$99.9m (up 73% from FY 2021). Profit margin: 2.6% (up from 1.8% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years, in line with the revenue forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Recent Insider Transactions • May 25MD, CEO & Executive Director recently bought €91k worth of stockOn the 24th of May, Gregory Hunt bought around 25k shares on-market at roughly €3.65 per share. This was the largest purchase by an insider in the last 3 months. This was Gregory's only on-market trade for the last 12 months.
Reported Earnings • May 20First half 2022 earnings releasedFirst half 2022 results: Revenue: (flat on 1H 2021). Net income: (flat on 1H 2021). Profit margin: (in line with 1H 2021). Over the next year, revenue is expected to shrink by 6.1% compared to a 6.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Buying Opportunity • Apr 23Now 23% undervaluedOver the last 90 days, the stock is up 56%. The fair value is estimated to be €5.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.1% per annum. Earnings is also forecast to grow by 20% per annum over the same time period.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 29% share price gain to €3.48, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 11x in the Chemicals industry in Germany. Total loss to shareholders of 2.8% over the past three years.
Reported Earnings • Nov 17Full year 2021 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$3.22b (up 100% from FY 2020). Net income: AU$65.1m (up AU$613.2m from FY 2020). Profit margin: 2.0% (up from net loss in FY 2020). The move to profitability was driven by higher revenue.
Breakeven Date Change • Jul 31Forecast breakeven pushed back to 2022The 12 analysts covering Nufarm previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of AU$75.3m in 2022. Average annual earnings growth of 33% is required to achieve expected profit on schedule.
Recent Insider Transactions • May 26MD, CEO & Executive Director recently bought €61k worth of stockOn the 24th of May, Gregory Hunt bought around 20k shares on-market at roughly €3.07 per share. This was the largest purchase by an insider in the last 3 months. Gregory has been a buyer over the last 12 months, purchasing a net total of €180k worth in shares.
Is New 90 Day High Low • Feb 26New 90-day high: €3.20The company is up 28% from its price of €2.50 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.12 per share.
Is New 90 Day High Low • Feb 04New 90-day high: €3.08The company is up 45% from its price of €2.12 on 06 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.69 per share.
Is New 90 Day High Low • Jan 20New 90-day high: €2.84The company is up 27% from its price of €2.24 on 22 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.53 per share.
Is New 90 Day High Low • Oct 21New 90-day low: €2.24The company is down 10.0% from its price of €2.48 on 22 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.89 per share.
Is New 90 Day High Low • Oct 02New 90-day low: €2.28The company is down 8.0% from its price of €2.48 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.00 per share.
Recent Insider Transactions • Sep 30Chairman of the Board recently bought €452k worth of stockOn the 28th of September, John Gillam bought around 185k shares on-market at roughly €2.44 per share. This was the largest purchase by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.
